A WSJ op-ed piece by Richard Miller, an oncologist and the CEO of the Bay Area-based Pharmacyclics, argues that the FDA needs to get cancer drugs to market quicker. Maybe he should direct his eye toward Scottish scientists at the universities of Glasgow and Strathclyde, who are developing a large molecular sensing device they plan to use to test for signature patterns of drug side effects. The main reason for drugs failing to pass clinical trials are the potential side effects, this BBC article quotes one of the leading scientists as having said.
When Faster IS Better
Dec 28, 2007